| 摘要 |
The present invention provides methods of treating schizophrenia and/or glucoregulatory abnormalities in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of formula I wherein in is 0, 1 or 2; n is 0, 1 or 2; p is 0 or 1; each R is independently hydrogen, halogen, trifluoromethyl, C<SUB>1</SUB>-C<SUB>6</SUB>alkyl, C<SUB>1</SUB>-C<SUB>6</SUB>alkoxy, benzyloxy, hydroxy, nitro or amino; each R<SUB>1 </SUB>is independently hydrogen, C<SUB>1</SUB>-C<SUB>6</SUB>alkyl, C<SUB>1</SUB>-C<SUB>6</SUB>alkenyl, C<SUB>1</SUB>-C<SUB>6</SUB>alkanoyl, halogen, cyano, -C(O)C<SUB>1</SUB>-C<SUB>6</SUB>alkyl, -C<SUB>1</SUB>-C<SUB>6</SUB>alkyleneCN, -C<SUB>1</SUB>-C<SUB>6</SUB>alkyleneNR'R'' wherein R' and R'' are each independently hydrogen or C<SUB>1</SUB>-C<SUB>6</SUB>alkyl, -C<SUB>1</SUB>-C<SUB>6</SUB>alkyleneOC(O)C<SUB>1</SUB>-C<SUB>6</SUB>alkyl, or -CH(OH)R<SUB>4 </SUB>wherein R<SUB>4 </SUB>is hydrogen or C<SUB>1</SUB>-C<SUB>6</SUB>alkyl; R<SUB>2 </SUB>is hydrogen, C<SUB>1</SUB>-C<SUB>6</SUB>alkyl optionally substituted with halogen, hydroxy or benlzyloxy, C<SUB>1</SUB>-C<SUB>6</SUB>alkenyl, C<SUB>1</SUB>-C<SUB>6</SUB>alkynyl, -CO<SUB>2</SUB>C<SUB>1</SUB>-C<SUB>6</SUB>alkyl, or -R<SUB>5</SUB>-NR'R'' wherein R<SUB>5 </SUB>is C<SUB>1</SUB>-C<SUB>6</SUB>alkylene, C<SUB>1</SUB>-C<SUB>6</SUB>alkenylene or C<SUB>1</SUB>-C<SUB>6</SUB>alkynylene and R' and R'' are each independently hydrogen, C<SUB>1</SUB>-C<SUB>6</SUB>alkyl or alternatively the group -NR'R'' as a whole is 1-pyrrolidinyl; and R<SUB>3 </SUB>is hydrogen, nitro, amino, halogen, C<SUB>1</SUB>-C<SUB>6</SUB>alkoxy, hydroxy or C<SUB>1</SUB>-C<SUB>6</SUB>alkyl or a pharmaceutically acceptable salt thereof.
|
